行情

ZGNX

ZGNX

Zogenix
NASDAQ

实时行情|Nasdaq Last Sale

24.81
+0.05
+0.20%
盘后: 24.00 -0.81 -3.26% 19:21 08/13 EDT
开盘
24.61
昨收
24.76
最高
25.20
最低
24.52
成交量
56.46万
成交额
--
52周最高
57.22
52周最低
16.65
市值
13.76亿
市盈率(TTM)
-2.6097
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ZGNX价格均价为48.36,最高价位69.00,最低价为25.00。

EPS

ZGNX 新闻

更多
Zogenix (ZGNX) Reports Q2 Loss, Misses Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 02:15
Zogenix EPS beats by $0.04, beats on revenue
Zogenix (NASDAQ:ZGNX): Q2 GAAP EPS of -$0.96 beats by $0.04. Revenue of $1.03M (-3.7% Y/Y) beats by $0.48M. Press Release
seekingalpha · 08/06 01:13
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
* FINTEPLA® (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S. * More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification * FDA meeting scheduled in September to discuss pla
GlobeNewswire · 08/05 20:01
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, a
GlobeNewswire · 07/29 12:00
Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Zogenix: A Critical Launch
Seeking Alpha - Article · 07/06 11:58
Zogenix's Long-Awaited Drug Approved With a Warning
Seizure medication must have black box warning due to safety issues Continue reading...
GuruFocus.com · 07/05 19:45
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
Zacks · 07/02 13:53

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

ZGNX 简况

Zogenix, Inc.是一家制药公司,致力于开发与商业化满足罕见与其他中枢神经系统(CNS)疾病患者特殊临床需求的CNS疗法。该公司的主要业务领域是癫痫和精神分裂症。该公司的主导候选产品ZX008是一种低剂量氟苯丙胺。该公司还从事Relday的开发,Relday是一种用于治疗成年人和13岁及以上青少年的精神分裂症和双相性精神障碍的长效利培酮注射制剂。该公司还从事制造Sumavel DosePro(舒马曲坦注射剂),一种销售给Endo Ventures Bermuda Limited和Endo Ventures Limited的无针给药系统。该公司的DosePro技术是一种为预填充单剂量液体药物皮下无针自行注射设计的给药系统。
展开

微牛提供Zogenix, Inc.(NASDAQ-ZGNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ZGNX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ZGNX股票基本功能。